Innovent Starts China Trial of LAG-3/PD-L1 Bispecific Antibody

Suzhou Innovent announced the first patient has been dosed in a China Phase I study of IBI323, an anti-LAG-3/PD-L1 bispecific antibody. The trial is enrolling patients with advanced solid tumors. In preclinical studies, IBI323 blocked both the PD-1/PD-L1 and LAG-3 pathways with the goal of generating more effective and durable T lymphocyte activation than administering the two molecules separately. Innovent's PD-1, Tyvyt® (sintilimab injection) is approved in China and its BLA is under review in the US . More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //